Literature DB >> 26202502

Comparison of hepatitis B surface antigen and e antigen in predicting liver histology in hepatitis B e antigen-positive chronic hepatitis B patients.

Hong Wang1, Rong Yan2, Yin Zhou3, Ming Shan Wang4, Guo Qin Ruo5, Mei Juan Cheng6.   

Abstract

BACKGROUND/AIM: The purpose of this study was to determine the relationship between hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels and liver histology in HBeAg-positive patients with chronic hepatitis B virus (CHB) infection.
METHODS: Serum HBsAg and HBeAg levels were analyzed, and liver biopsies were obtained from 203 HBeAg-positive CHB patients (62.6 % males; median age 31.3 years). The upper limit of normal (ULN) for ALT in this study was 30 and 19 U/L for males and females, respectively. Histologic assessment was based on Scheuer classification.
RESULTS: ALT <2 × ULN, fibrosis stage <S2, and necro-inflammation grade <G2 were noted in 70 (34.5 %), 141 (69.5 %), and 105 (51.7 %) patients, respectively. Patients with significant histology (fibrosis stage ≥S2 and/or fibrosis stage of 1 plus inflammation grade ≥2) had significantly lower median HBsAg (13,998.4 and 42,186.5 IU/mL, respectively, p < 0.001) and HBeAg levels (540.5 and 1,206.8 S/CO, respectively, p < 0.001) than patients with insignificant histology. Among patients with ALT <2 × ULN, the area under the ROC curve for serum HBsAg and HBeAg levels was 0.76 and 0.70, respectively. Using a cutoff value of 17,558 IU/mL for HBsAg and 875.6 S/CO for HBeAg in patients with ALT <2×ULN, positive predictive values for insignificant histology were 87 and 86.8 %, respectively, whereas the negative predictive values were 50 and 47.1 %, respectively.
CONCLUSIONS: Among HBeAg-positive patients with ALT <2 × ULN, high-serum HBsAg and HBeAg levels can equally accurately predict insignificant histology.

Entities:  

Keywords:  Aminotransferase; Biopsy; Hepatitis B e antigen; Hepatitis B surface antigen; Hepatitis B virus; Liver fibrosis

Year:  2014        PMID: 26202502     DOI: 10.1007/s12072-013-9502-8

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  28 in total

1.  Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.

Authors:  Maurizia Rossana Brunetto; Filippo Oliveri; Piero Colombatto; Francesco Moriconi; Pietro Ciccorossi; Barbara Coco; Veronica Romagnoli; Beatrice Cherubini; Giovanna Moscato; Anna Maria Maina; Daniela Cavallone; Ferruccio Bonino
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

2.  Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection.

Authors:  Rahmet Guner; Mustafa Karahocagil; Mehmet Buyukberber; Ozlem Kandemir; Onur Ural; Gaye Usluer; Dilara Inan; Iftihar Koksal; Nurcan Baykam; Kenan Hizel; Tansu Yamazhan; Saban Esen; Mehmet A Tasyaran
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 2.566

Review 3.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

4.  Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B.

Authors:  J H Kwon; J W Jang; S Lee; J Lee; K W Chung; Y S Lee; J Y Choi
Journal:  J Viral Hepat       Date:  2011-11-20       Impact factor: 3.728

Review 5.  EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Authors: 
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

6.  Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients.

Authors:  Michelle Martinot-Peignoux; Roberto Carvalho-Filho; Martine Lapalus; Ana Carolina Ferreira Netto-Cardoso; Olivier Lada; Richard Batrla; Friedemann Krause; Tarik Asselah; Patrick Marcellin
Journal:  J Hepatol       Date:  2013-01-28       Impact factor: 25.083

7.  Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

Authors:  Jerzy Jaroszewicz; Beatriz Calle Serrano; Karsten Wursthorn; Katja Deterding; Jerome Schlue; Regina Raupach; Robert Flisiak; C-Thomas Bock; Michael P Manns; Heiner Wedemeyer; Markus Cornberg
Journal:  J Hepatol       Date:  2010-02-13       Impact factor: 25.083

8.  Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.

Authors:  M-F Yuen; H-J Yuan; D K-H Wong; J C-H Yuen; W-M Wong; A O-O Chan; B C-Y Wong; K-C Lai; C-L Lai
Journal:  Gut       Date:  2005-05-04       Impact factor: 23.059

9.  A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen.

Authors:  Margaret T Chen; Jean-Noel Billaud; Matti Sällberg; Luca G Guidotti; Francis V Chisari; Joyce Jones; Janice Hughes; David R Milich
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-05       Impact factor: 11.205

10.  A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B.

Authors:  Wai-Kay Seto; Ching-Lung Lai; Philip P C Ip; James Fung; Danny Ka-Ho Wong; John Chi-Hang Yuen; Ivan Fan-Ngai Hung; Man-Fung Yuen
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

View more
  3 in total

1.  Development and validation of a model for staging hepatic fibrosis for chronic hepatitis B patients with E antigen-positive.

Authors:  Hong Wang; Ying Zhou; Rong Yan; Guo Qing Ru; Li Li Yu; Ming Shan Wang; Mei Juan Chen
Journal:  Oncotarget       Date:  2017-10-24

2.  A Noninvasive Score to Predict Liver Fibrosis in HBeAg-Positive Hepatitis B Patients with Normal or Minimally Elevated Alanine Aminotransferase Levels.

Authors:  Yanping Chen; Yanping Li; Na Li; Xiude Fan; Chunyan Li; Pingping Zhang; Qunying Han; Zhengwen Liu
Journal:  Dis Markers       Date:  2018-10-14       Impact factor: 3.434

3.  Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients.

Authors:  Bengü Tatar; Ayse Acar; Pelın Adar; Sukran Kose
Journal:  Clin Exp Hepatol       Date:  2020-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.